U.S. markets closed
  • S&P 500

    3,831.39
    +6.06 (+0.16%)
     
  • Dow 30

    30,967.82
    -129.44 (-0.42%)
     
  • Nasdaq

    11,322.24
    +194.39 (+1.75%)
     
  • Russell 2000

    1,741.33
    +13.57 (+0.79%)
     
  • Crude Oil

    99.55
    -8.88 (-8.19%)
     
  • Gold

    1,763.80
    -37.70 (-2.09%)
     
  • Silver

    19.14
    -0.53 (-2.71%)
     
  • EUR/USD

    1.0268
    -0.0156 (-1.50%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • GBP/USD

    1.1957
    -0.0147 (-1.21%)
     
  • USD/JPY

    135.8390
    +0.1790 (+0.13%)
     
  • BTC-USD

    20,243.66
    +463.74 (+2.34%)
     
  • CMC Crypto 200

    443.95
    +3.93 (+0.89%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,423.47
    +269.66 (+1.03%)
     

Human Longevity plans to go public in $1 bln blank-check deal

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

June 20 (Reuters) - Genome sequencing company Human Longevity Inc plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1 billion, the two companies said on Monday.

The announcement followed the signing of a non-binding letter of intent, although the companies said that there is no assurance of a definitive agreement or completion of a deal.

Freedom Acquisition I Corp is a special purpose acquisition company led by former Credit Suisse chief executive Tidjane Thiam, and was listed early last year.

A blank-check firm, or a special purpose acquisition company (SPAC), is a listed shell entity that uses the money raised in its IPO to merge with a private company, taking it public in the process. (Reporting by Leroy Leo in Bengaluru; editing by Richard Pullin)